학술논문
Pro-Inflammatory and Pro-Oxidative Changes during Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)
Document Type
Article
Author
Sicuranza, Anna; Ferrigno, Ilaria; Abruzzese, Elisabetta; Iurlo, Alessandra; Galimberti, Sara; Gozzini, Antonella; Luciano, Luigiana; Stagno, Fabio; Russo Rossi, Antonella; Sgherza, Nicola; Cattaneo, Daniele; Zuanelli Brambilla, Corrado; Marzano, Cristina; Fava, Carmen; Mulas, Olga; Cencini, Emanuele; Gozzetti, Alessandro; Puccetti, Luca; Bocchia, Monica
Source
Blood; November 2021, Vol. 138 Issue: 1, Number 1 Supplement 1 p1479-1479, 1p
Subject
Language
ISSN
00064971; 15280020
Abstract
Background:Tyrosine kinase inhibitors (TKI) may offer a normal life expectancy to Chronic Myeloid Leukemia (CML) patients. However, during treatment with nilotinib, a higher than expected incidence of arterial occlusive events (AOEs) was observed. We retrospectively showed an “inflammatory status” during nilotinib treatment that may explain this increased incidence of AOEs. Here, we report results of a prospective multicenter (KIARO) study including 186 CML patients (89 imatinib, 59 nilotinib, 38 dasatinib) in which pro/anti-inflammatory cytokines were measured at diagnosis and during treatment, with the aim to investigate potential changes in each patient's inflammatory status possibly favoring AOEs.